trial

Schizophrenia Study In Adults

NCTId NCT00049946
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 231
Sponsored by GlaxoSmithKline
Primary completion 2003-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
231
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2002-10
Primary completion
2003-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
TalnetantRisperidone

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

31 total
Scottsdale, United StatesCerritos, United StatesChula Vista, United StatesGarden Grove, United StatesOrange, United StatesPico Rivera, United StatesRosemead, United StatesSacramento, United StatesSan Diego, United StatesSan Diego, United StatesNew Britain, United StatesNew Haven, United States

Linked catalysts

1
Schizophrenia Study In Adults — primary completion2003-04

Facts & assertions

4 sourced
Enrollment
231
Phase
PHASE2
Primary Completion Date
2003-04
Status
COMPLETED
relationships
The graph out of here
drug
Talnetant
drug
Risperidone
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication